Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART: Role of HCV genotypes

Ivana Maida, Sergio Babudieri, Cinzia Selva, Gianpiero D'Offizi, Luisa Fenu, Giuliana Solinas, Pasqualino Narciso, Maria Stella Mura, Marina Núnez

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1%) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0%), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4%) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.

Original languageEnglish
Pages (from-to)139-143
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume22
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Highly Active Antiretroviral Therapy
Hepacivirus
Genotype
HIV
Liver
Enzymes
Transaminases
RNA
Cellular Immunity
Incidence
Serology
Therapeutics
CD4 Lymphocyte Count
Population

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART : Role of HCV genotypes. / Maida, Ivana; Babudieri, Sergio; Selva, Cinzia; D'Offizi, Gianpiero; Fenu, Luisa; Solinas, Giuliana; Narciso, Pasqualino; Mura, Maria Stella; Núnez, Marina.

In: AIDS Research and Human Retroviruses, Vol. 22, No. 2, 02.2006, p. 139-143.

Research output: Contribution to journalArticle

Maida, Ivana ; Babudieri, Sergio ; Selva, Cinzia ; D'Offizi, Gianpiero ; Fenu, Luisa ; Solinas, Giuliana ; Narciso, Pasqualino ; Mura, Maria Stella ; Núnez, Marina. / Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART : Role of HCV genotypes. In: AIDS Research and Human Retroviruses. 2006 ; Vol. 22, No. 2. pp. 139-143.
@article{d099dd1ee85a42c6b23471974428bbdb,
title = "Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART: Role of HCV genotypes",
abstract = "Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1{\%}) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0{\%}), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4{\%}) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.",
author = "Ivana Maida and Sergio Babudieri and Cinzia Selva and Gianpiero D'Offizi and Luisa Fenu and Giuliana Solinas and Pasqualino Narciso and Mura, {Maria Stella} and Marina N{\'u}nez",
year = "2006",
month = "2",
doi = "10.1089/aid.2006.22.139",
language = "English",
volume = "22",
pages = "139--143",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Liver enzyme elevation in hepatitis C virus (HCV) - HIV-coinfected patients prior to and after initiating HAART

T2 - Role of HCV genotypes

AU - Maida, Ivana

AU - Babudieri, Sergio

AU - Selva, Cinzia

AU - D'Offizi, Gianpiero

AU - Fenu, Luisa

AU - Solinas, Giuliana

AU - Narciso, Pasqualino

AU - Mura, Maria Stella

AU - Núnez, Marina

PY - 2006/2

Y1 - 2006/2

N2 - Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1%) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0%), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4%) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.

AB - Transaminase elevation is frequently seen in hepatitis C virus (HCV)-HIV-coinfected patients receiving antiretroviral therapy (ART), representing an increase in the immune response against HCV and being one of the mechanisms proposed to be involved. There is a report claiming that HCV genotype 3 is an independent risk factor. Our objectives were to assess the incidence of liver toxicity in an HIV-HCV-coinfected population with relatively preserved cellular immunity, and the role of HCV genotypes in the elevation of liver enzymes, both at baseline and after initiating ART. All HIV + patients with positive anti-HCV serology and CD4 + cell counts above 100/mm 3 who began triple ART were identified, and their HCV-RNA levels and HCV genotype were determined. Liver enzymes were determined at baseline and bimonthly during follow-up. Of anti-HCV patients 147 were included, 128 (87.1%) of whom had detectable plasma HCV-RNA. HCV-1 and HCV-4 genotypes were found to confer an increased probability of having at baseline transaminases within normal limits over the other genotypes. Severe transaminase elevations (grades 3 and 4) occurred in 5/124 patients (4.0%), all with high pre-HAART ALT and positive HCV-RNA levels. Multivariate analysis showed that patients with genotype HCV-3 had a 3.27 times higher risk of developing HAART-related transaminase elevations of any grade. In conclusion, subjects with the HCV-1 genotype more often had transaminases within normal limits at baseline. The incidence of severe transaminase elevation after initiating ART was very low (4%) in this HIV + population with relatively preserved cellular immunity. HCV genotype 3 was identified as a risk factor for the development of transaminase elevation of any grade.

UR - http://www.scopus.com/inward/record.url?scp=33244484852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244484852&partnerID=8YFLogxK

U2 - 10.1089/aid.2006.22.139

DO - 10.1089/aid.2006.22.139

M3 - Article

C2 - 16478395

AN - SCOPUS:33244484852

VL - 22

SP - 139

EP - 143

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -